Wednesday, December 17, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Smith & Wesson’s Mixed Quarter: A Tale of Two Firearm Segments

Andreas Sommer by Andreas Sommer
November 1, 2025
in Analysis, Defense & Aerospace, Earnings, Turnaround
0
Smith & Wesson Brands Stock
0
SHARES
11
VIEWS
Share on FacebookShare on Twitter

Smith & Wesson Brands has unveiled quarterly results that paint a complex picture for the firearms manufacturer. While the company posted a net loss of $3.4 million, or $0.08 per share, it managed to surpass analyst expectations. Revenue for the period declined by 3.7% to $85.1 million, accompanied by a contraction in the gross margin, which fell from 27.4% to 25.9%.

Diverging Product Performance

A deep dive into the product segments reveals a story of two extremes. The handgun business experienced a powerful surge, with unit shipments skyrocketing by 35%, significantly outpacing overall industry demand. This robust performance, however, was entirely offset by a severe downturn in the long gun category. Revenue from long guns plummeted to $13.6 million from $24.7 million, as shipments collapsed by 28.1%, dropping from 39,000 units to 26,000 units. The company attributes this sharp decline to its limited presence in the currently soft markets for shotguns and bolt-action rifles.

On a positive note, the company’s focus on innovation yielded tangible results, with newly introduced products contributing 37.3% to the total revenue.

Should investors sell immediately? Or is it worth buying Smith & Wesson Brands?

Stock Performance and Market Sentiment

The market’s reaction has been decidedly negative, with the stock price reflecting a sustained downward trend. After recording losses for four consecutive trading sessions, shares are now trading at $9.77. This price level brings the stock closer to its 52-week low of $7.73, while the yearly high of $14.20 seems a distant memory.

  • Market experts have largely consolidated their ratings to “Hold.”
  • The consensus price target among analysts sits at $12.00.
  • The current breakdown of recommendations includes one “Buy,” two “Hold,” and one “Sell.”

All eyes are now on the next quarterly report, scheduled for December 4th, which is expected to be a critical indicator of whether Smith & Wesson can orchestrate a meaningful turnaround.

Ad

Smith & Wesson Brands Stock: Buy or Sell?! New Smith & Wesson Brands Analysis from December 17 delivers the answer:

The latest Smith & Wesson Brands figures speak for themselves: Urgent action needed for Smith & Wesson Brands investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 17.

Smith & Wesson Brands: Buy or sell? Read more here...

Tags: Smith & Wesson Brands
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Gilead Sciences Stock
Analysis

Gilead Sciences Advances HIV Treatment with Promising Phase 3 Trial Results

December 17, 2025
Atlassian Stock
Analysis

Insider Selling Adds Pressure to Atlassian’s Struggling Shares

December 17, 2025
Clover Health Investments Registered (A) Stock
Analysis

Clover Health Investors Await Crucial Strategy Presentation

December 17, 2025
Next Post
Insight Stock

Is There a Floor in Sight for Insight's Plummeting Shares?

Terex Stock

Terex Shares Plunge Amid Major Strategic Overhaul

MSCI World ETF Stock

Global Equity ETF Powers to Record Gains on Tech Strength

Recommended

Wabash National Stock

Wabash National Shares Face Sustained Decline

1 month ago
Pfizer Stock

Pfizer’s Narrow Vaccine Approval Presents Commercial Challenge

4 months ago
FirstCash Stock

FirstCash Shares Surge Following Exceptional Quarterly Performance

1 month ago
Laboratory of America Stock

Labcorp Shares Face Divergent Analyst Views Amid Growth Strategy

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Clover Health Investors Await Crucial Strategy Presentation

SunHydrogen Shares Face Mounting Technical Pressure

Cardano’s Critical Juncture: Technical Gains Clash With Market Realities

Brazilian Airline Gol Faces Legal Hurdle in Bankruptcy Proceedings

Bloom Energy Shares Face a Reality Check as AI Infrastructure Costs Soar

Dow Jones Consolidates Following Record Peak

Trending

Quantum Computing Stock
AI & Quantum Computing

Quantum Computing Stock Pivots with Major Acquisition

by Dieter Jaworski
December 17, 2025
0

The quantum computing sector is witnessing a strategic shift as Quantum Computing moves to acquire Luminar Semiconductor....

Gilead Sciences Stock

Gilead Sciences Advances HIV Treatment with Promising Phase 3 Trial Results

December 17, 2025
Atlassian Stock

Insider Selling Adds Pressure to Atlassian’s Struggling Shares

December 17, 2025
Clover Health Investments Registered (A) Stock

Clover Health Investors Await Crucial Strategy Presentation

December 17, 2025
SunHydrogen Stock

SunHydrogen Shares Face Mounting Technical Pressure

December 17, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Quantum Computing Stock Pivots with Major Acquisition
  • Gilead Sciences Advances HIV Treatment with Promising Phase 3 Trial Results
  • Insider Selling Adds Pressure to Atlassian’s Struggling Shares

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com